⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 28, 2016Arthritis Research & TherapyOpen Access

Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment

Matthieu Lavielle Denis Mulleman Philippe Goupille Clément Bahuaud Hsueh Cheng Sung Hervé Watier Gilles Thibault

View Full Paper

Ask AI

Bookmark

Share

Abstract

CD4+ T-cell counts could be a relevant biomarker of response to rituximab in rheumatoid arthritis and could be considered in making decisions about the timing of retreatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lavielle et al. (2016) studied this question.

synapsesocial.com/papers/69dbd630c9a120f055a3cb36 https://doi.org/10.1186/s13075-016-1152-5

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksRCT · 2006 · 1,638 citations
2Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisRCT · 2004 · 2,626 citations
3Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritisCohort Study · 2008 · 210 citations
4Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritisOriginal Research · 2006 · 560 citations
5Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical responseOriginal Research · 2009 · 135 citations

More related papers

Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis2009
Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritis2006
B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six‐month, national, multicenter, open‐label study2011

More from Arthritis Research & Therapy

Nocebo effect of nintedanib on gastrointestinal events in interstitial lung diseasesFri,
Comorbidity management in inflammatory rheumatic diseases: a dual-perspective survey of patients and rheumatologistsFri,